Eltrombopag is recommended as an option for treating chronic immune (idiopathic) thrombocytopenic purpura in adults, only if:
their condition is refractory to standard active treatments and rescue therapies or
they have severe disease and a high risk of bleeding that needs frequent courses of rescue therapies.
Eltrombopag is recommended only if the company provides it with the discount agreed in the patient access scheme.
1.2 These recommendations are not intended to affect treatment with eltrombopag that was started in the NHS before this guidance was published. People having treatment outside these recommendations may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.